Harrison Global forms partnership with Korean biotech firm

TOKYO - Harrison Global Holdings Inc. (NASDAQ:BLMZ), a micro-cap company with a market capitalization of $2.81 million, has entered into a strategic international business partnership with Biotree Co., Ltd., a Korean company developing a natural product-based treatment for metabolic syndrome, according to a press release issued Tuesday. While the stock has seen a strong return over the last month, InvestingPro data shows it has declined over 84% in the past year.

Biotree has completed Phase 1 clinical trials in the United States for its PH-100 treatment and Phase 2A clinical trials across 12 university hospitals in Korea. The Phase 2A results showed a significant reduction in inflammatory markers and positive effects on cardiovascular disease without adverse side effects.

The treatment is expected to be conditionally approved and launched as a prescription-only medication in the first half of 2026, pending successful completion of ongoing Phase 2B clinical trials.

Under the partnership, Harrison Global plans to support the global expansion of Biotree’s technology and raw materials for metabolic syndrome treatments to markets including the US, Japan, China, and other Asian countries. Despite reporting 71.48% revenue growth in the last twelve months, InvestingPro analysis indicates the company is quickly burning through cash, with negative EBITDA of $1.2 million.

The collaboration will encompass establishing joint ventures or licensing agreements, developing new natural product drugs, sharing distribution channels, introducing local partners, and providing regulatory compliance support.

Biotree has extracted "Seapolynol," a marine polyphenol, from Gamtae seaweed, and has developed products across health functional foods, pharmaceuticals, daily necessities, and cosmetics. The company has obtained certifications including the U.S. FDA’s New Dietary Ingredient and Investigational New Drug designations.

"Through this partnership, we are delighted to contribute to human health by working with Biotree to complete the development of a natural metabolic syndrome treatment," said Ryoshin Nakade, Co-CEO of Harrison Global Holdings, in the statement.

Harrison Global Holdings, formerly known as BloomZ Inc., operates primarily in audio production for anime and games, and manages voice actors and VTubers in Japan. The company maintains a healthy current ratio of 2.81, indicating strong short-term liquidity. InvestingPro subscribers can access 8 additional key insights about BLMZ’s financial health and growth prospects.

In other recent news, Harrison Global Holdings Inc. has entered into an agreement to acquire a majority stake in Myth Korea Inc., a South Korean company. This acquisition aims to develop a pop culture lifestyle and experiential retail store, with plans to open a Pokémon Card Center in Busan, South Korea by October 2025. Harrison Global has also announced a strategic partnership with South Korean company GRAPES Inc. to expand AI-powered music production and virtual entertainment across Asian markets. This collaboration focuses on establishing K-pop and K-culture content infrastructure in several countries, including Japan, China, and the United States. Additionally, Harrison Global has begun due diligence for a potential acquisition of Idealize Co., Ltd., a Japanese event operations and audio-visual production company. This move aims to enhance its capabilities in hosting events featuring VTubers and virtual characters. Meanwhile, BloomZ Inc. has been granted a second 180-day extension to meet Nasdaq’s minimum bid price requirement, allowing the company until December 1, 2025, to comply with the $1.00 per share rule. Despite previous efforts, BloomZ was unable to meet the requirement within the initial period, and the Nasdaq Listing Qualification Staff has now determined that BloomZ is eligible for this additional compliance period.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.